ATE448248T1 - Mutante fab fragmente des chimären anti-cd4 antikörpers 13b8.2 und ihre verwendungen - Google Patents

Mutante fab fragmente des chimären anti-cd4 antikörpers 13b8.2 und ihre verwendungen

Info

Publication number
ATE448248T1
ATE448248T1 AT03755580T AT03755580T ATE448248T1 AT E448248 T1 ATE448248 T1 AT E448248T1 AT 03755580 T AT03755580 T AT 03755580T AT 03755580 T AT03755580 T AT 03755580T AT E448248 T1 ATE448248 T1 AT E448248T1
Authority
AT
Austria
Prior art keywords
antibody
fab fragments
chimeric anti
mutant fab
mutant
Prior art date
Application number
AT03755580T
Other languages
English (en)
Inventor
Christian Devaux
Cedric Bes
Laurence Briant-Longuet
Martine Cerutti
Gerard Devauchelle
Thierry Chardes
Claude Granier
Bernard Pau
Original Assignee
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient filed Critical Centre Nat Rech Scient
Application granted granted Critical
Publication of ATE448248T1 publication Critical patent/ATE448248T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT03755580T 2002-07-05 2003-07-07 Mutante fab fragmente des chimären anti-cd4 antikörpers 13b8.2 und ihre verwendungen ATE448248T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0208486A FR2841905B1 (fr) 2002-07-05 2002-07-05 Fragments fab mutants de l'anticorps anti-cd4 chimere 13b8.2 et leurs applications
PCT/FR2003/002108 WO2004005350A2 (fr) 2002-07-05 2003-07-07 Fragments fab mutans de l'anticorps anti-cd4 chimere 13b8.2 et leurs applications

Publications (1)

Publication Number Publication Date
ATE448248T1 true ATE448248T1 (de) 2009-11-15

Family

ID=29725219

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03755580T ATE448248T1 (de) 2002-07-05 2003-07-07 Mutante fab fragmente des chimären anti-cd4 antikörpers 13b8.2 und ihre verwendungen

Country Status (9)

Country Link
US (1) US7482000B2 (de)
EP (1) EP1519960B1 (de)
JP (1) JP2006513138A (de)
AT (1) ATE448248T1 (de)
AU (1) AU2003273423A1 (de)
CA (1) CA2490708A1 (de)
DE (1) DE60330007D1 (de)
FR (1) FR2841905B1 (de)
WO (1) WO2004005350A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1227321A1 (de) * 2000-12-28 2002-07-31 Institut für Bioanalytik GmbH Funktionelle Reinigung von Antigen spezifischen T Lymphozyten durch Peptide-MHC Multimer Färbung
US9023604B2 (en) 2011-07-18 2015-05-05 Iba Gmbh Method of reversibly staining a target cell
JP6362543B2 (ja) 2012-02-23 2018-07-25 ジュノ セラピューティクス ゲーエムベーハー 細胞および他の複雑な生物学的材料のクロマトグラフィーによる単離
LT3132247T (lt) 2014-04-16 2021-12-10 Juno Therapeutics Gmbh Ląstelių populiacijos padauginimo būdai, rinkiniai ir priemonės
IL313845A (en) 2014-04-23 2024-08-01 Juno Therapeutics Inc Methods for enriching or producing immune cell populations for adoptive therapy
WO2016166568A1 (en) 2015-04-16 2016-10-20 Juno Therapeutics Gmbh Methods, kits and apparatus for expanding a population of cells
CN108474791B (zh) 2015-10-22 2022-07-08 朱诺治疗学有限公司 培养细胞的方法及用于该方法的试剂盒和设备
US11466253B2 (en) 2015-10-22 2022-10-11 Juno Therapeutics Gmbh Methods for culturing cells and kits and apparatus for same
HK1258932A1 (zh) 2015-10-22 2019-11-22 Juno Therapeutics Gmbh 用於转导的方法、反应剂盒、反应剂和设备
EP3336545A1 (de) 2016-12-13 2018-06-20 Miltenyi Biotec GmbH Reversible markierung von antigenen in biologischen proben
MA49288A (fr) 2017-04-27 2020-03-04 Juno Therapeutics Gmbh Reactifs particulaires oligomères et leurs méthodes d'utilisation
SG11202101204TA (en) 2018-08-09 2021-03-30 Juno Therapeutics Inc Processes for generating engineered cells and compositions thereof
EP3874024A1 (de) 2018-10-31 2021-09-08 Juno Therapeutics GmbH Verfahren zur selektion und stimulation von zellen und vorrichtung dafür
JP7604366B2 (ja) 2018-11-06 2024-12-23 ジュノー セラピューティクス インコーポレイテッド 遺伝子操作されたｔ細胞を作製するための方法
EP4022637A2 (de) 2019-08-30 2022-07-06 Juno Therapeutics, Inc. Maschinenlernverfahren zum klassifizieren von zellen
WO2021084050A1 (en) 2019-10-30 2021-05-06 Juno Therapeutics Gmbh Cell selection and/or stimulation devices and methods of use
KR20230022868A (ko) 2020-05-13 2023-02-16 주노 쎄러퓨티크스 인코퍼레이티드 재조합 수용체를 발현하는 공여자-배치 세포의 제조 방법
JP2024517863A (ja) 2021-05-06 2024-04-23 ジュノ・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 細胞を刺激し、形質導入する方法
WO2023147510A1 (en) 2022-01-28 2023-08-03 Juno Therapeutics, Inc. Chromatography arrays and related methods and kits
WO2023213969A1 (en) 2022-05-05 2023-11-09 Juno Therapeutics Gmbh Viral-binding protein and related reagents, articles, and methods of use
EP4615960A1 (de) 2022-11-09 2025-09-17 C3S2 GmbH Verfahren zur herstellung von manipulierten immunzellen
CN121100267A (zh) 2022-12-09 2025-12-09 朱诺治疗学股份有限公司 使用全息成像预测细胞表型的机器学习方法
CN121002052A (zh) 2023-02-03 2025-11-21 C3S2 有限公司 用于非病毒生产工程化免疫细胞的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020099179A1 (en) * 1989-12-21 2002-07-25 Linda K. Jolliffe Cdr-grafted antibodies
WO1993008216A1 (en) * 1991-10-15 1993-04-29 New York University Human monoclonal antibodies to the cd4-binding domain of hiv, uses thereof and synergistic neutralization of hiv
US5728821A (en) * 1994-08-04 1998-03-17 Bristol-Myers Squibb Company Mutant BR96 antibodies reactive with human carcinomas

Also Published As

Publication number Publication date
FR2841905B1 (fr) 2004-09-03
WO2004005350A3 (fr) 2004-04-08
FR2841905A1 (fr) 2004-01-09
WO2004005350A2 (fr) 2004-01-15
EP1519960A2 (de) 2005-04-06
AU2003273423A8 (en) 2004-01-23
AU2003273423A1 (en) 2004-01-23
US7482000B2 (en) 2009-01-27
CA2490708A1 (fr) 2004-01-15
JP2006513138A (ja) 2006-04-20
US20050226874A1 (en) 2005-10-13
EP1519960B1 (de) 2009-11-11
DE60330007D1 (de) 2009-12-24

Similar Documents

Publication Publication Date Title
DE60330007D1 (de) Mutante fab fragmente des chimären anti-cd4 antikörpers 13b8.2 und ihre verwendungen
WO2005003171A3 (en) Modified antibody fragments
CY1110877T1 (el) Αλλαγη των συγγενειων συνδεσης me fcrn ή των ημιζωων ορου αντισωματων με μεταλλαξιγενεση
NZ607711A (en) Antibodies directed to her-3 and uses thereof
EP2684889A3 (de) Mit einem zielgerichteten menschlichen monoklonalen Antikörper komplexierte multivariable Antigene
CY1116632T1 (el) Εξουδετερωτες αντισωματων του τελεστη διεγερσης αποικιων κοκκιοκυτταρων μακροφαγων ανθρωπου
WO2005003169A3 (en) Modified antibody fab fragments
WO2005003170A3 (en) Modified antibody fragments
CY1108799T1 (el) Αντισωμα αντι- ccr5
NZ599683A (en) Anti-ilt7 antibody
SE0401601D0 (sv) Protofibril specific antibodies and uses thereof
CY1109390T1 (el) Εξανθρωπισμενο anti-cd4 αντισωμα με ανοσοκατασταλτικες ιδιοτητες
ATE490275T1 (de) Antikörper gegen interleukin-22 und verwendungen dafür
DE602005022928D1 (de) Antikörper gegen gpnmb und ihre verwendungen
CY1112862T1 (el) Θραυσματα μονοσθενους αντισωματος χρησιμα ως θεραπευτικα
CY1110759T1 (el) Παραλλαγες ανοσοσφαιρινων και χρησεις αυτων
ATE370967T1 (de) Polyspezifische bindemoleküle und deren verwendung
UA89017C2 (uk) ЛЮДСЬКЕ АНТИТІЛО, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ЛЮДСЬКИМ TNFSF13b
ATE395082T1 (de) Antikörper gegen krebsantigen tmeff2 und seine anwendungen
DE60238533D1 (de) Nicht-depletierender Antikörper TRX-1 gegen CD4 und dessen Verwendungen
WO2006102200A3 (en) Docetaxel immunoassay
ECSP066432A (es) Moléculas de enlace terapéuticas
WO2004050849A3 (en) Recombinant immunotoxin and use in treating tumors
WO2006015098A3 (en) Taxol immunoassay
DK1572745T3 (da) Antistof anti-humant NogoA og dets farmaceutiske anvendelse

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties